Department of Psychological Science, University of California, Irvine, CA, USA; Department of Psychiatry and Behavioral Sciences, Rush University Medical Center, Chicago, IL, USA.
Department of Internal Medicine, Rush University Medical Center, Chicago, IL, USA; Rush Center for Integrated Microbiome and Chronobiology Research, Rush University Medical Center, Chicago, IL, USA; Department of Anatomy & Cell Biology, Rush University Medical Center, Chicago, IL, USA.
J Psychiatr Res. 2024 May;173:1-5. doi: 10.1016/j.jpsychires.2024.02.045. Epub 2024 Feb 27.
Brain derived neurotrophic factor (BDNF) may play an important role in the success of treatment for posttraumatic stress disorder (PTSD). Pre- and post-treatment blood samples were analyzed for 40 veterans who completed a 3-week intensive outpatient treatment for PTSD. The treatment included Cognitive Processing Therapy, mindfulness, and yoga as core treatment components. PTSD symptoms were assessed at pre-treatment, post-treatment, and 3-month follow-up. Participants reported large decreases in PTSD symptoms from pre-to post-treatment (d = 1.46, p < 0.001) and pre-treatment to 3-month follow-up (d = 0.91, p < 0.001). Unexpectedly, participants demonstrated a decrease in BDNF from pre-to post-treatment (d = 0.64, p < 0.001). Changes in BDNF from pre-to post-treatment were not significantly associated with PTSD symptom improvement. However, higher levels of post-treatment BDNF were significantly associated with lower PTSD symptoms at 3-month follow-up (n = 27, r = -0.57, p = 0.002) and greater improvements in PTSD symptoms from pre-treatment to 3-month follow-up (n = 27, r = 0.50, p = 0.008). Higher levels of post-treatment BDNF may facilitate the long-term success of intensive PTSD treatment. Further research with larger samples is needed to evaluate the processes by which BDNF may affect consolidation of improvements after completion of PTSD treatment.
脑源性神经营养因子（BDNF）可能在创伤后应激障碍（PTSD）治疗的成功中发挥重要作用。对完成 PTSD 为期 3 周的强化门诊治疗的 40 名退伍军人进行了治疗前和治疗后血样分析。该治疗包括认知加工疗法、正念和瑜伽作为核心治疗成分。在治疗前、治疗后和 3 个月随访时评估 PTSD 症状。参与者报告 PTSD 症状从治疗前到治疗后（d=1.46，p<0.001）和治疗前到 3 个月随访（d=0.91，p<0.001）有较大的减少。出乎意料的是，参与者的 BDNF 从治疗前到治疗后减少（d=0.64，p<0.001）。BDNF 从治疗前到治疗后的变化与 PTSD 症状的改善没有显著相关。然而，治疗后 BDNF 水平较高与 3 个月随访时 PTSD 症状较低（n=27，r=-0.57，p=0.002）以及从治疗前到 3 个月随访时 PTSD 症状改善较大（n=27，r=0.50，p=0.008）显著相关。较高的治疗后 BDNF 水平可能会促进 PTSD 强化治疗的长期成功。需要更大样本的进一步研究来评估 BDNF 可能影响 PTSD 治疗完成后改善巩固的过程。
